News

Minivelle, which the company claims is the smallest estrogen patch, is bioequivalent to company’s Vivelle, (estradiol transdermal system) and is 34% smaller than Vivelle-Dot. The company said Minivelle,

Total revenue for fourth quarter of 2012 was $5.96bn compared to $6.05bn for the fourth quarter of 2011. The company reported a net income of $4.09bn, or $3.66

The JV will formulate Leuprolide in a proprietary controlled-release drug delivery platform technology, developed by Foresee. Under the JV, ScinoPharm will act as the exclusive provider of Leuprolide

Under the deal, Afraxis will earn around $187.5m in total as upfront, research, development and commercialization milestone payments. Afraxis president and CEO and Avalon Ventures managing partner Jay

The completion of cGMP manufacturing, which resulted in a high yield batch of DM-199, allows the company to use DM-199 compound in its upcoming clinical trials. The company

The partnership will focus on developing and validating the diagnostic EP-AD assay for use as both a biomarker, useful in AD related clinical studies, and an FDA-approved AD

The regulatory agency approved Kynamro 200mg subcutaneous injection per week as an added therapy to lipid-lowering medications and diet in HoFH patients. Kynamro will reduce low density lipoprotein-cholesterol

The renewal was followed by a cGMP inspection conducted by Spanish health authorities at the manufacturing facility. TiGenix CTO Wilfried Dalemans said the Madrid GMP facility manufactures high-quality,

Lonza completed validation of viral-induced cell processing GMP suites and completed the tech transfer process. Lonza viral-based therapeutics head David Enloe said, "We are pleased to have been